Professor Daniel Rea
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
university of brimingham
Norway
Biography
Dr Rea is deputy Director of the Cancer Research UK Clinical Trials unit with responsibility for the phase III trials activity of the unit. The current portfolio of late phase trials includes multiple tumour sites. The trials unit has produced a number of trials over the past decade that hve directly impacted on clinical practice as well as improve our understanding of the treatment of a wide range of malignancies.
Research Interest
His own interests are in breast cancer research. He is the Chief Investigator for the aTTom Trial which has recently reported results demonstrating the clinical importance of prolonged adjuvant tamoxifen for early breast cancer and the TEAM study which has prospectively established the value of different hormonal strategies. Recent translational studies from this International Trial have provided statistically robust data to understand the relationship between hormone receptor, HER1-3 expression and differential endocrine sensitivity. Further translational work is being conducted to evaluate the importance of many pathway abnormalities and their relationship to hormonal sensitivity. New Breast Cancer studies an exploration of biomarker driven chemotherapy selection in neoadjuvant chemotherapy and a trial to establish the safety of observation rather than immediate surgery for low grade ductal carcinoma in situ.
